Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €67.12 EUR
Change Today -0.64 / -0.94%
Volume 48.4K
As of 6:12 AM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

ucb sa (UCB) Snapshot

Open
€67.85
Previous Close
€67.76
Day High
€68.05
Day Low
€66.81
52 Week High
08/29/14 - €75.62
52 Week Low
10/16/14 - €59.01
Market Cap
13.1B
Average Volume 10 Days
278.1K
EPS TTM
€1.13
Shares Outstanding
194.5M
EX-Date
05/4/15
P/E TM
59.4x
Dividend
€1.06
Dividend Yield
1.58%
Current Stock Chart for UCB SA (UCB)

Related News

No related news articles were found.

ucb sa (UCB) Related Businessweek News

No Related Businessweek News Found

ucb sa (UCB) Details

UCB S.A., a biopharmaceutical company, focuses on the discovery and development of medicines and solutions for people living with severe diseases of the immune system or of the central nervous system in Belgium and internationally. The company’s core products include Cimzia for Crohn’s disease, rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis/ankylosing spondylitis; Vimpat for the treatment of epilepsy partial-onset seizures (POS); and Neupro for Parkinson’s disease and restless legs syndrome. It also offers Keppra for epilepsy POS, epilepsy primary generalized tonic-clonic seizures (PGTCS), and epilepsy myoclonic seizures; Zyrtec and Xyzal for allergy; Metadate for attention deficit and hyperactivity disorders; Nootropil for the treatment of psycho-organic syndromes or cognitive decline and cortical myoclonus; and Xyrem for narcolepsy with cataplexy in adult patients. In addition, the company provides Tussionex for relief of cough and upper respiratory symptoms associated with allergy or a cold; and Lortab for the relief from pain. The company’s product pipeline includes brivaracetam as an adjunctive therapy for epilepsy POS; Vimpat for various types of epilepsy; UCB4942 for drug resistant epilepsy; epratuzumab for systemic lupus erythematosus; romosozumab for osteoporosis; UCB4940 for psoriatic arthritis; UCB5857 for immune-inflammatory diseases; UCB7665 for immunological diseases; and dapirolizumab pegol for systemic lupus erythematosus. The company has strategic alliances with the Weill Cornell Medical College (U.S.), Sanofi, and Dermira Inc., as well as collaboration agreement with Neuropore Therapies Inc. UCB S.A. was founded in 1928 and is headquartered in Brussels, Belgium.

8,535 Employees
Last Reported Date: 02/28/15
Founded in 1928

ucb sa (UCB) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

ucb sa (UCB) Key Developments

UCB Reports Revenue Results for the First Half of 2015: Provides Earnings Guidance for the Year 2015

UCB reported earnings results for the first half of 2015. For the period, the company reported 21% year-on-year rise in revenues to EUR 1.917 billion. The revenues were mainly driven by the better-than-expected sales performance of the company's core products. The company is now forecasting total revenues to reach between EUR 3.65 billion and EUR 3.75 billion. This compares to a previous full-year revenues forecast of between EUR 3.55 billion and EUR 3.65 billion in 2015.

UCB Reported Consolidated Earnings Results for the First Half Ended June 30, 2015; Revises Earnings Guidance for the Full Year of 2015

UCB reported consolidated earnings results for the first half ended June 30, 2015. For the period, the company reported revenue of EUR 1,917 million against EUR 1,591 million a year ago. Net sales were EUR 1,704 million against EUR 1,406 million a year ago. Recurring EBIT (REBIT) was EUR 335 million against EUR 198 million a year ago. EBIT (operating profit) was EUR 415 million against EUR 152 million a year ago. Profit before income taxes was EUR 369 million against EUR 85 million a year ago. Profit from continuing operations was EUR 261 million against EUR 62 million a year ago. Net profit attributable to company's shareholders was EUR 267 million against EUR 137 million a year ago. Recurring EBITDA was EUR 464 million against EUR 311 million a year ago. Capital expenditures (including intangible assets) were EUR 97 million against EUR 91 million a year ago. Net financial debt as at June 30, 2015 was EUR 1,813 million. Cash flow from continuing activities was EUR 136 million against EUR 174 million a year ago. EPS (per weighted average number of shares - non diluted) was EUR 1.39 against EUR 0.72 a year ago. Core EPS (per weighted average number of shares - non diluted) was EUR 1.18 against EUR 0.96 a year ago. For 2015, the company's revenue is now expected in the range of EUR 3.65 billion to EUR 3.75 billion and recurring EBITDA is now expected at the higher end of the previous range of EUR 710 million to EUR 740 million. Core earnings per share (EPS) are expected in the range of EUR 1.90 to EUR 2.05 based on an average of 192 million shares outstanding.

UCB, SA Announces Two Embody Phase 3 Clinical Trials for Epratuzumab in Systemic Lupus Erythematosus Does Not Meet Primary Clinical Efficacy Endpoints

On July 28, 2015, Immunomedics Inc. reported that licensing partner, UCB, SA, announced that the two EMBODY Phase 3 clinical trials for epratuzumab in Systemic Lupus Erythematosus (SLE) did not meet the primary clinical efficacy endpoints in either dose in both studies. Treatment response in patients who received epratuzumab in addition to standard therapy was not statistically significant when compared to those who received placebo in addition to standard therapy. UCB is in the process of analyzing the full set of results from both studies. A high level review of the safety data did not identify any new safety concerns. In May 2006, UCB and the company entered into a Development, Collaboration and License Agreement providing UCB an exclusive worldwide license to develop, manufacture, market and sell epratuzumab for the treatment of all autoimmune disease indications. The Collaboration Agreement was amended by the parties in December 2011.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
UCB:BB €67.12 EUR -0.64

UCB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Endo International PLC $79.00 USD +2.62
Grifols SA €36.56 EUR -0.245
Hospira Inc $89.92 USD +0.08
Lonza Group AG SFr.129.60 CHF -0.60
Sigma-Aldrich Corp $139.65 USD +0.64
View Industry Companies
 

Industry Analysis

UCB

Industry Average

Valuation UCB Industry Range
Price/Earnings 47.2x
Price/Sales 3.5x
Price/Book 2.4x
Price/Cash Flow 38.0x
TEV/Sales 2.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact UCB SA, please visit www.ucb.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.